Is tamoxifen the Rosetta stone for breast cancer? - PubMed

Review

Is tamoxifen the Rosetta stone for breast cancer?

V Craig Jordan. J Natl Cancer Inst. 2003.

Comment on

• Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.

  Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R. Osborne CK, et al. J Natl Cancer Inst. 2003 Mar 5;95(5):353-61. doi: 10.1093/jnci/95.5.353. J Natl Cancer Inst. 2003. PMID: 12618500

Similar articles

• Hormones 'R' us.

  Sledge GW Jr. Sledge GW Jr. Clin Breast Cancer. 2002 Jan;2(4):251. doi: 10.3816/cbc.2002.n.001. Clin Breast Cancer. 2002. PMID: 11899355 No abstract available.

• Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.

  Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R. Osborne CK, et al. J Natl Cancer Inst. 2003 Mar 5;95(5):353-61. doi: 10.1093/jnci/95.5.353. J Natl Cancer Inst. 2003. PMID: 12618500

• Is low-dose tamoxifen useful for the treatment and prevention of breast cancer?

  Wu K, Brown P. Wu K, et al. J Natl Cancer Inst. 2003 Jun 4;95(11):766-7. doi: 10.1093/jnci/95.11.766. J Natl Cancer Inst. 2003. PMID: 12783921 Review. No abstract available.

• Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.

  Dixon JM, Jackson J, Renshaw L, Miller WR. Dixon JM, et al. J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):295-9. doi: 10.1016/s0960-0760(03)00370-4. J Steroid Biochem Mol Biol. 2003. PMID: 14623524 Review.

• Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.

  Moy I, Lin Z, Rademaker AW, Reierstad S, Khan SA, Bulun SE. Moy I, et al. PLoS One. 2013 Nov 6;8(11):e77543. doi: 10.1371/journal.pone.0077543. eCollection 2013. PLoS One. 2013. PMID: 24223121 Free PMC article.

Cited by

• A nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer.

  Zhou C, He Jj, Li J, Fan Jh, Zhang B, Yang Hj, Xie Xm, Tang Zh, Li H, Li Jy, Wang Sl, Qiao Yl, Huang R, Zhang P. Zhou C, et al. PLoS One. 2014 Jul 18;9(7):e100159. doi: 10.1371/journal.pone.0100159. eCollection 2014. PLoS One. 2014. PMID: 25036532 Free PMC article.

• Translating cancer research into targeted therapeutics.

  de Bono JS, Ashworth A. de Bono JS, et al. Nature. 2010 Sep 30;467(7315):543-9. doi: 10.1038/nature09339. Nature. 2010. PMID: 20882008

• Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells.

  Dougherty SM, Mazhawidza W, Bohn AR, Robinson KA, Mattingly KA, Blankenship KA, Huff MO, McGregor WG, Klinge CM. Dougherty SM, et al. Endocr Relat Cancer. 2006 Mar;13(1):113-34. doi: 10.1677/erc.1.01118. Endocr Relat Cancer. 2006. PMID: 16601283 Free PMC article.

• Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs.

  Cyrus K, Wehenkel M, Choi EY, Lee H, Swanson H, Kim KB. Cyrus K, et al. ChemMedChem. 2010 Jul 5;5(7):979-85. doi: 10.1002/cmdc.201000146. ChemMedChem. 2010. PMID: 20512796 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal